News of the WeekBIOTERRORISM

BioShield Is Slow to Build U.S. Defenses Against Bioweapons

Science  07 Jul 2006:
Vol. 313, Issue 5783, pp. 28-29
DOI: 10.1126/science.313.5783.28

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Summary

Developing vaccines against potential bioweapons such as smallpox and Marburg virus is tough going for small companies. But it's even harder when their comrade-in-arms on the front lines, a $5.6 billion federal program called BioShield, is AWOL. (Read more.)

Related Content